Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

EMA committee hands down positive opinion on burosumab for X-linked hypophosphatemia

Dec. 18, 2017

Jnana Therapeutics launches with series A financing to target metabolic genes

Dec. 18, 2017

Protagonist Therapeutics reports topline results from PTG-300 phase I study

Dec. 15, 2017

FDA grants fast track designation to WTX-101 for Wilson's disease

Dec. 15, 2017

Akcea begins phase II trial of AKCEA-ANGPTL3-LRx

Dec. 15, 2017

Amicus Therapeutics applies for U.S. approval of migalastat for Fabry disease

Dec. 15, 2017

Asklepios announces formation of new portfolio company Actus Therapeutics

Dec. 15, 2017

SLC22A12 inhibitors described in Institute of Materia Medica of Beijing patent

Dec. 14, 2017

JCR reports topline results from phase I/II study of JR-141 in Hunter's syndrome

Dec. 14, 2017

reMYND and Novo Nordisk enter license agreement for ReS-39 in diabetes

Dec. 14, 2017

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...